Through our efforts aimed at social implementation of advanced medicine, such as support of life science research and development of gene therapy, we are working to create a society in which people can stay well and enjoy life.
Takara Bio Group offers a wide variety of products and services in the life sciences field, ranging from those for basic research to those with industrial applications. We are supporting the growth of research in the life sciences by providing universities and businesses around the world with a stable supply of these products.
We will develop need-oriented products and ensure their stable supply, from research products for the life sciences to test reagents for diagnosis of infectious diseases
Tsuyoshi Miyamura, Director
In Coronavirus Catastrophe, we prioritized rapid development, manufacturing system optimization, and stable supply for products related to COVID-19 PCR testing. We are putting effort toward using the genetic engineering technology we cultivated through our research reagents business as a platform to develop products that test for viruses that cause infectious diseases, as well as products tailored to regional characteristics. At the same time, we are working to ensure a stable supply of these products. To accomplish this, we are working on infrastructure improvements at our manufacturing hubs from a global perspective.
In addition, to ensure customer satisfaction with our products, we are also deepening communication with the life sciences community through efforts such as improving our online catalog and holding events such as seminars and workshops.
As demand for PCR testing grows amidst the pandemic, we are working to build up the testing system by strengthening our production system and providing a stable supply of PCR-related products and internationally.
We have also actively expanded our genetic analysis technology to testing and diagnostics, and are helping people be well by expanding the scope of this technology.
We have also been working to improve access to medical care for rare diseases by leveraging the biotechnology we have cultivated over many years in clinical development of gene therapy for rare cancers and other rare diseases. We are aiming to bring socially impactful regenerative medicine products such as gene therapies to market through our CDMO business to address unmet medical needs.
We are aiming for technological development and social implementation of gene therapy
Junichi Mineno, Director
Takara Bio has been developing gene therapies for a long time, and our current projects include engineered T cell therapy. We are also leveraging our experience in developing these products to actively expand our CDMO business, where we support development and manufacturing of regenerative medicine products such as vaccines and gene therapies. These treatments we are developing are new modalities that use genes and cells as drugs, and show promise for treating and improving patient QOL for diseases for which sufficiently effective treatments have not yet been established. However, this is a still-developing field, and many issues remain to be solved.
In our sustainability activities, we name Wellness” as one of the materialities (important issues), and going forward, we plan to continue solving many issues that exist with gene therapy, and actively pursue technological development, capital investment, and education of specialized personnel to achieve social implementation and address these difficult challenges.
|